Scarica l'app Stockscreener
15.48
4.31%
0.64
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Arcturus Therapeutics Holdings Inc Borsa (ARCT) Ultime notizie
State Street Corp Sells 50,883 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
We're Not Very Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate - Yahoo Finance
Arcturus Therapeutics stock hits 52-week low at $14.82 - Investing.com India
Wellington Management Group LLP Lowers Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics stock hits 52-week low at $14.82 By Investing.com - Investing.com Canada
Arcturus Therapeutics' (ARCT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - StockTitan
Arcturus Therapeutics' SWOT analysis: mRNA vaccine stock faces pivotal year - Investing.com
Cantor Fitzgerald Reaffirms "Overweight" Rating for Arcturus Therapeutics (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics Holdings (NASDAQ:ARCT shareholders incur further losses as stock declines 9.8% this week, taking three-year losses to 63% - Simply Wall St
Fmr LLC Sells 112,516 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers - Yahoo Finance
10 Worst ARK Stocks To Buy According to Short Sellers - Insider Monkey
mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider - GlobeNewswire Inc.
Arcturus Therapeutics (NASDAQ:ARCT) Shares Up 13.3%Here's Why - MarketBeat
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma - The Eastern Progress Online
Arcturus Therapeutics' SWOT analysis: vaccine maker's stock faces challenges, opportunities - Investing.com Nigeria
Portolan Capital Management LLC Sells 355,763 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
ARCT (Arcturus Therapeutics Holdings) Enterprise Value : $279.5 Mil (As of Dec. 04, 2024) - GuruFocus.com
Urea Cycle Disorder Treatment Market to Grow by USD 215.4 Million (2024-2028), Driven by Rising Prevalence, with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve
PDT Partners LLC Buys Shares of 75,144 Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Arcturus Therapeutics to Attend Upcoming Investor Conferences - BioSpace
Arcturus Therapeutics to Present at Major Healthcare Investor Conferences in December - StockTitan
GSA Capital Partners LLP Has $219,000 Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference - Yahoo Finance
Sumitomo Mitsui Trust Group Inc. Buys 712,650 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Avian Flu: FDA Authorizes Self-Replicating Vaccine Trial to Bill Gates-Backed Company, "Study Can Proceed" - presskit.it
Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data (NASDAQ:ARCT) - Seeking Alpha
Meiji Seika Pharma Invests in ARCALIS to Boost Japan's mRNA Vaccine Production | ARCT Stock News - StockTitan
Arcturus gains IND clearance for H5N1 influenza sa-RNA vaccine candidate - BioWorld Online
Possible Signal As Arcturus Therapeutics Holdings Insiders Sell US$1.6m In Stock - Simply Wall St
Another Avian Influenza mRNA Vaccine Candidate Advances - Precision Vaccinations
Arcturus Therapeutics Holdings Inc. Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial - Marketscreener.com
What is HC Wainwright's Estimate for ARCT FY2028 Earnings? - MarketBeat
Arcturus Therapeutics’ (ARCT) Buy Rating Reiterated at HC Wainwright - Defense World
Arcturus Gets FDA Green Light for H5N1 Flu mRNA Vaccine Trial, Backed by BARDA - StockTitan
Earnings call: Arcturus Therapeutics reported a net loss of $6.9 million - Investing.com Australia
Arcturus Therapeutics Holdings Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2024 Earnings Call Transcript - Insider Monkey
Nikko Asset Management Americas, Inc. Expands Stake in Arcturus Therapeutics Holdings Inc. - GuruFocus.com
Arcturus Therapeutics (NASDAQ:ARCT) Receives "Buy" Rating from HC Wainwright - MarketBeat
ARK Investment Management LLC Has $48.77 Million Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $71.40 Average Target Price from Brokerages - Defense World
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call - GuruFocus.com
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call Highlights: Strategic Advances ... - Yahoo Finance
Arcturus Therapeutics Reports Q3 2024 Financial Results and Milestones - TipRanks
Arcturus Therapeutics Holdings Inc earnings beat by $0.31, revenue fell short of estimates - Investing.com
ARCTArcturus Therapeutics Holdings Inc. Latest Stock News & Market Updates - StockTitan
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Arcturus Therapeutics: Q3 Earnings Snapshot - Marketscreener.com
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):